Further Information
T-lymphocyte activation antigen CD86, Activation B7-2 antigen, B70, BU63, CTLA-4 counter-receptor B72, FUN-1, CD86, CD86, CD28LG2
Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 0.5-1 ug/ml
Western blot: 0.5-1 ug/ml
Immunohistochemistry (FFPE): 2-4 ug/ml for 30 min at RT (1)
Optimal dilution of the CD86 antibody should be determined by the researcher.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris buffer with 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 min.
Recognizes a protein of 70kDa, which is identified as CD86. CD86 is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily of cell surface receptors. It is expressed at high levels on resting peripheral monocytes and dendritic cells and at very low density on resting B and T lymphocytes. CD86 expression is rapidly upregulated by B cell specific stimuli with peak expression at 18 to 42 hours after stimulation. CD86, along with CD80/B71, is an important accessory molecule in T cell co-stimulation via its interaction with CD28 and CD152/CTLA4. Since CD86 has rapid kinetics of induction, it is believed to be the major CD28 ligand expressed early in the immune response. It is also found on malignant Hodgkin and Reed Sternberg (HRS) cells in Hodgkin's disease.
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
0.2 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Recombinant human full-length protein was used as the immunogen for the CD86 antibody.
942
CD86 molecule
CD86
Homo sapiens
Liquid
Protein G affinity chromatography
Immunology,Signal Transduction
P42081
Optimal dilutions for each application to be determined by the researcher